Bexson Biomedical Presents Battlefield-Optimized Wearable Ketamine Device and Novel Therapy to U.S. Military Innovation Leaders

July 13, 2023

Santa Barbara, Calif. — Bexson Biomedical, Inc., a biopharmaceutical company focused on enabling health delivery solutions through their novel formulation technology for subcutaneous delivery, was one of four companies to present at a Ft. Detrick Medical Innovation Day earlier this week. Hosted by the U.S. military, the four companies at the event presented their disruptive solutions for battlefield healthcare delivery.  

Bexson Biomedical’s CEO, Gregg Peterson, demonstrated the AKESO wearable drug delivery device and discussed the Company’s BB106 ketamine therapy for pain management. 

AKESO, specifically designed for the more rugged use requirements of austere and contested environments, is being developed in collaboration with Bexson’s device partner, Stevanato Group S.p.A. (NYSE: STVN), a leader in medical device and drug delivery technologies. 

The combination of AKESO and BB106 is designed to provide non-opioid pain management on the battlefield, offering a significant improvement over current intravenous (IV) ketamine delivery.

By reducing the need for heavy saline bags and the complexity of initiating IV delivery on the battlefield, we believe the AKESO device will substantially lower the weight required to carry ketamine therapy and significantly improve the time to initiate pain therapy, representing meaningful improvements for both patient and field medical personnel.

Bexson Biomedical, Inc.

Bexson Biomedical, Inc. is a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health delivery. Bexson’s proprietary formulation platform, SEVALENTTM, can be applied to small molecules across a broad range of drug classes, enabling intravenous (IV) therapies to be delivered subcutaneously.  

Bexson’s lead therapy, BB106, is a low-dose ketamine treatment for post-operative pain management, a $36B global market and leading driver of opioid addiction. Additionally, management believes its BB106 therapy can be utilized to address various mental health indications.  

Bexson Biomedical, Inc. Contact Information

Investor Relations please contact Matthew Pigeon

Press inquiries please contact Teresa Bigelow at